FDA's Hepcludex Approval for HDV: A Long-Overdue Entry Inhibitor Milestone, Yet Real-World Durability and Access Gaps Remain

The FDA's accelerated approval of bulevirtide (Hepcludex) for chronic hepatitis delta virus (HDV) infection represents the first targeted therapy for a virus that accelerates fibrosis and hepatocellular carcinoma far faster than HBV or HCV alone. Unlike the MedicalXpress summary, which focuses narrowly on the 48-week viral suppression rates from the Phase III RCT (20% undetectable HDV RNA vs 0% delayed treatment), deeper context reveals this as the culmination of entry-inhibitor research dating to 2014 preclinical work on NTCP receptor blockade. The trial, an open-label RCT with likely modest sample size (typical for orphan HDV studies, around 150-200 participants), demonstrated rising suppression to 50% by week 144 but omitted hard clinical endpoints like decompensation or survival, relying instead on surrogate RNA clearance under accelerated approval. A key missed element in coverage is the European experience since 2020 conditional approval, where real-world cohorts showed 40-60% response rates but highlighted rebound hepatitis upon discontinuation, aligning with the boxed warning. Synthesizing with peer-reviewed sources: the pivotal MYR301 RCT (published in Lancet Infectious Diseases, n=174, low risk of bias but industry-funded by Gilead) and a 2023 observational cohort in Hepatology (n=112, non-randomized, potential selection bias) underscore that while bulevirtide outperforms historical interferon regimens (which had <30% sustained response and high toxicity), combination strategies with nucleos(t)ide analogs may be needed for HBV co-suppression. Conflicts of interest are evident in Gilead's sponsorship across trials. Broader patterns show HDV's underdiagnosis in high-prevalence regions like Central Asia and Eastern Europe, where access barriers could limit this breakthrough's impact despite orphan designation.